KeifeRx is dedicated to improving the treatment of neurodegenerative and immune diseases and bringing relief to the millions of people worldwide who are impacted by these debilitating, life-diminishing conditions.
KeifeRx seeks to leverage mechanisms of action inherent to TKIs which thus far have been underexplored: the ability to penetrate the brain, induce autophagy, and enable the bulk disposal of disease-causing toxic proteins to treat neurodegenerative diseases, and the ability to target mast cells and simultaneously modulate peripheral and central immunity, providing therapeutic potential for an array of immune diseases.
These properties offer the potential to significantly improve upon current neurodegenerative and immune disease treatments, which are primarily palliative and offer minimal and temporary benefits due to their inability to adequately eliminate toxic proteins and mitigate inflammation.
KeifeRx is currently investigating or plans to investigate its TKI formulations in neurodegenerative diseases, including Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI), and movement disorders, including Lewy Body Dementia (LBD) and Amyotrophic Lateral Sclerosis (ALS) and Huntington’s disease. Additionally, KeifeRx is advancing novel TKIs targeting inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria, as well as neuro-inflammatory conditions that are features of neurodegeneration.
KeifeRx’s clinical pipeline is led by KFRX01 (Nilotinib BE), an optimized re-formulation with improved bioavailability and solubility than nilotinib (Tasgina®). KFRX01 is being developed for the treatment of early Alzheimer’s disease.
Keiferx CEO on new method for treating Alzheimer’s, neurodegenerative disease
Disposing Toxic Proteins to Treat Neurodegenerative Diseases
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors